Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sean Tu

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
JAMA|March 12, 2025
Drug Versioning and Legal Accountability for Preventable Product HarmsS Sean Tu, Timothy Bonis
JAMA|August 29, 2023
Free Speech Challenges to the Inflation Reduction ActS Sean Tu, Rebecca Tushnet
JAMA|July 16, 2025
Drug Versioning and Legal Accountability-ReplyS Sean Tu, Timothy Bonis
The New England Journal of Medicine|April 21, 2026
Anticompetitive Mergers - Pharmaceutical Buyouts as a Strategy for Maintaining Market DominanceS Sean Tu, Jaime King
The New England Journal of Medicine|February 3, 2023
A "Method of Use" to Prevent Generic and Biosimilar Market EntryS Sean Tu, Ameet Sarpatwari
JAMA Health Forum|July 19, 2024
Use of Track One Prioritized Examination for Pharmaceutical PatentsS Sean Tu, William B Feldman
Clinical Pharmacology and Therapeutics|October 24, 2023
Preserving Timely Generic Drug Competition with Legislation on "Skinny Labeling"S Sean Tu, Aaron S Kesselheim
JAMA Health Forum|November 14, 2025
Mapping Intellectual Property Abuses in the Pharmaceutical FieldS Sean Tu, Ana Santos Rutschman
JAMA Health Forum|June 5, 2026
When Constitutional Theory Collides With Health Care Accountability-The False Claims Act at a CrossroadsAaron S Kesselheim, S Sean Tu
JAMA Health Forum|February 28, 2025
Using Trademarks to Ensure Completion of Postapproval TrialsCatherine S Hwang, S Sean Tu
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
JAMA|March 12, 2025
Drug Versioning and Legal Accountability for Preventable Product HarmsS Sean Tu, Timothy Bonis
JAMA|August 29, 2023
Free Speech Challenges to the Inflation Reduction ActS Sean Tu, Rebecca Tushnet
JAMA|July 16, 2025
Drug Versioning and Legal Accountability-ReplyS Sean Tu, Timothy Bonis
The New England Journal of Medicine|April 21, 2026
Anticompetitive Mergers - Pharmaceutical Buyouts as a Strategy for Maintaining Market DominanceS Sean Tu, Jaime King
The New England Journal of Medicine|February 3, 2023
A "Method of Use" to Prevent Generic and Biosimilar Market EntryS Sean Tu, Ameet Sarpatwari
JAMA Health Forum|July 19, 2024
Use of Track One Prioritized Examination for Pharmaceutical PatentsS Sean Tu, William B Feldman
Clinical Pharmacology and Therapeutics|October 24, 2023
Preserving Timely Generic Drug Competition with Legislation on "Skinny Labeling"S Sean Tu, Aaron S Kesselheim
JAMA Health Forum|November 14, 2025
Mapping Intellectual Property Abuses in the Pharmaceutical FieldS Sean Tu, Ana Santos Rutschman
JAMA Health Forum|June 5, 2026
When Constitutional Theory Collides With Health Care Accountability-The False Claims Act at a CrossroadsAaron S Kesselheim, S Sean Tu
JAMA Health Forum|February 28, 2025
Using Trademarks to Ensure Completion of Postapproval TrialsCatherine S Hwang, S Sean Tu
Pageof 6